Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Executive Summary
Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.
You may also be interested in...
Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely
Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will likely need to dovetail with President Trump’s agenda to advance.
Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.